Olema Oncology at Stifel 2026 Healthcare Conference 2026: key trial inflection

On November 11, 2026, Olema Oncology (OLMA) shared updates about its breast cancer pipeline during the Stifel 2026 Healthcare Conference. The company highlighted two promising trials: palazestrant and OP-3136. However, the main concern was whether late-stage data would validate earlier signals and support a future launch. Olema is exploring near-term catalysts, including a Phase III readout in early 2025, new combination data in December, and a potential mid-2028 launch.

The company's cash position was a strong point, with $414 million available at the end of Q3 2024, which should support operations during the palazestrant launch window. The company emphasized that access to capital will be crucial depending on the success of its lead studies. Olema sees OPERA-01 as the main value driver, with potential positive results in both ESR1-mutant and wild-type breast cancer markets.

The ESR1-mutant market is valued at $2 billion annually, while the ESR1 wild-type market is valued at $3 billion without direct competition. If both parts of OPERA-01 succeed, the total addressable market could reach $5 billion.

OP-3136, Olema's KAT6 inhibitor, is advancing with interest, and the company is also exploring palazestrant as a potential combination partner. Management is preparing for a U.S. launch and seeking an ex-U.S. collaborator. The company's balance sheet is strong, with $414 million in cash and a current ratio of 6.12, but it has burned through $165 million in levered free cash flow over the past year.

Olema aims to secure multiple financing options, not just equity, and maintain a focus on palazestrant, its oral selective estrogen receptor degrader (SERD).